0000950142-17-001798.txt : 20171003 0000950142-17-001798.hdr.sgml : 20171003 20171003174207 ACCESSION NUMBER: 0000950142-17-001798 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171003 FILED AS OF DATE: 20171003 DATE AS OF CHANGE: 20171003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wygant Jonathan CENTRAL INDEX KEY: 0001584145 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16789 FILM NUMBER: 171119485 MAIL ADDRESS: STREET 1: 3750 TORREY VIEW COURT CITY: SAN DIEGO STATE: X1 ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALERE INC. CENTRAL INDEX KEY: 0001145460 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 043565120 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 51 SAWYER ROAD STREET 2: SUITE 200 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7816473900 MAIL ADDRESS: STREET 1: 51 SAWYER ROAD STREET 2: SUITE 200 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: INVERNESS MEDICAL INNOVATIONS INC DATE OF NAME CHANGE: 20010720 4 1 es1701022_4-wygant.xml OWNERSHIP DOCUMENT X0306 4 2017-10-03 1 0001145460 ALERE INC. ALR 0001584145 Wygant Jonathan 51 SAWYER ROAD SUITE 200 WALTHAM MA 02453 0 1 0 0 VP, Controller, CAO Common Stock 2017-10-03 4 D 0 1909 D 0 D Restricted Stock Units 2017-10-03 4 D 0 6666 D Common Stock 6666 0 D Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. /s/ Doug Barry, Attorney-in-Fact 2017-10-03